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Immune recovery in HIV-infected patients after
Candida esophagitis is impaired despite long-term
antiretroviral therapy
Claudia Stuehlera,M, Claudia Bernardinia,b,M, Luigia Elzib,
Marcel Stoeckleb, Stefan Zimmerlic, Hansjakob Furrerc,
Huldrych F. Gu¨nthardd,e, Salome´ Leibundgut-Landmannf,
Manuel Battegayb, Nina Khannaa,b, the Swiss HIV Cohort Study
Objective: Candida esophagitis belongs to the most common AIDS-defining diseases;
however, a comprehensive immune pathogenic concept is lacking.
Design: We investigated the immune status of 37 HIV-1-infected patients from the
Swiss HIV cohort study at diagnosis of Candida esophagitis, 1 year before, 1 year later
and after 2 years of suppressed HIV RNA. We compared these patients with three
groups: 37 HIV-1-infected patients without Candida esophagitis but similar CD4þ cell
counts as the patients at diagnosis (advanced HIV group), 15 HIV-1-infected patients
with CD4þ cell counts higher than 500 cells/ml, CD4þ cell nadirs higher than 350 cells/
ml and suppressed HIV RNA under combination antiretroviral therapy (cART)
(early cART group) and 20 healthy individuals.
Methods: We investigated phenotype, cytokine production and proliferative capacity
of different immune cells by flow cytometry and enzyme-linked immunosorbent spot.
Results: We found that patients with Candida esophagitis had nearly abolished CD4þ
cell proliferation in response toCandida albicans, significantly increased percentages of
dysfunctional CD4þ cells, significantly decreased cytotoxic natural killer cell counts
and peripheral innate lymphoid cell counts and significantly reduced IFN-g and IL-17
production compared with the early cART group and healthy individuals. Most of these
defects remained for more than 2 years despite viral suppression. The advanced HIV
group without opportunistic infection showed partly improved immune recovery.
Conclusion: Our data indicate that Candida esophagitis in HIV-1-infected patients is
caused by an accumulation of multiple, partlyCandida-specific immunological defects.
Long-term immune recovery is impaired, illustrating that specific immunological gaps
persist despite cART. These data also support the rationale for early cART initiation
to prevent irreversible immune defects.
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Introduction
The risk of opportunistic infections in patients with HIV
infection has markedly declined since 1996 because of the
widespread use of combination antiretroviral therapy
(cART) [1]. Nevertheless, opportunistic infections still
remain a leading complication with an incidence of 16%
in late presenting patients [2]. Absolute CD4þ cell counts
less than 200 cells/ml and uncontrolled HIV RNA
replication are well described major risk factors for the
development of opportunistic infection, yet they also
occur in patients with CD4þ cell counts higher than 200
cells/ml with an incidence of 10.5 per 1000 patient-years
follow-up, highlighting that apart from the absolute
CD4þ cell counts, additional risk factors for opportunistic
infection must be present [3]. This is further supported by
recent studies documenting that early initiation of cART
at CD4þ cell counts higher than 500 cells/ml is beneficial
as it significantly reduces the risk for opportunistic
infection and malignancies [4,5], yet opportunistic
infections are not completely eliminated. It remains
uncertain why certain HIV-infected patients are suscept-
ible to specific opportunistic infections and how the
infection influences long-term immune recovery.
Candida esophagitis is one of the most common AIDS-
defining diseases, occurring in up to 10–15% of HIV-
infected patients before introduction of cART [1,6,7].
Importantly, Candida esophagitis is often the first
opportunistic infection and also develops in patients
with rather high CD4þ cell counts suggesting that the
functionality of immune responses is diminished [7].
Earlier studies considered that susceptibility to Candida
esophagitis is enhanced by a lack of protective Th1
responses and/or a shift to Th2 responses [8]. However,
recent studies show that individuals with impaired IL-17
responses exhibit enhanced susceptibility to chronic
mucocutaneous candidiasis [9]. In the context of HIV,
progressive infection is accompanied by continuous loss
of Th17 cells [10] and a decrease in the ratio of Th17 to
Th1 cells in peripheral blood [11]. Recently, it has been
demonstrated in a mouse model of oropharyngeal
candidiasis that IL-17 secreting RORgtþ type 3 innate
lymphoid cells (ILCs) also contribute to fungal clearance
[12]. Moreover, natural killer (NK) cells are increasingly
considered as part of the host defense against fungi [13],
and their function was shown to be impaired against
Cryptococcus neoformans in HIV-infected patients [14].
In this study, we took the advantage of prospectively
stored patient samples within the Swiss HIV Cohort
Study (SHCS) and investigated the numbers and
functions of different immune cell subsets in patients
with Candida esophagitis over a longitudinal follow-up,
including samples before disease development and after
long-term suppression of HIV RNA and compared them
with three groups of individuals, including HIV-infected
patients with similarly advanced HIV infection
without opportunistic infection, HIV-infected patients
that initiated cART at CD4þ cell nadirs higher than
350 cells/ml and were HIV RNA suppressed and healthy
individuals.
Methods
Patients and healthy blood donors
The Swiss HIV Cohort Study is a large prospective
observational cohort study with continuous enrolment of
adult HIV-infected individuals initiated in 1988 and
approved by the local institutional review boards [15].
Basic socio-demographic characteristics, data on clinical
course, antiretroviral therapy, immunologic and virologic
parameters are collected at enrolment and every 6 months
thereafter. Viable peripheral blood mononuclear cells
(PBMC) and plasma are stored every 6–12 months.
Ethical approval and written informed consent from all
patients enrolled in the SHCS have been obtained.
The diagnosis Candida esophagitis was based on clinical
findings defined according to Centers for Disease Control
and Prevention (CDC) criteria [16]. From January 2000
until December 2013, 465 HIV-1 infected patients
were diagnosed with Candida esophagitis. Of these,
277 patients had Candida esophagitis as first and only
AIDS-defining disease. Of these, 37 patients with
available longitudinal PBMCwere included.We analyzed
cryopreserved PBMC from three time points:
6–18 months before diagnosis, at diagnosis (6 months)
and 6–18 months after diagnosis. For patients with
suppressed HIV RNA (<50 copies/ml) over 2 years, an
additional time point was included. These patients were
compared with three groups. First, HIV-1-infected
patients with similarly advanced disease but without
opportunistic infection. Patients were matched to
Candida esophagitis patients according to CD4þ cell
counts (25 cells/ml), date of diagnosis of Candida
esophagitis, use of cART, sex, age and absence of other
opportunistic infection within 6 months prior to sample
collection [17]. As for the Candida esophagitis patients,
four time points were analyzed. Second, 15 SHCS
patients with well controlled HIV-1 infection from
outpatients of the HIV clinic at the University Hospital of
Basel. Patients had the following criteria: HIV CDC A1
or A2 classification with suppressed HIV RNA (<50
copies/ml) and stable cART therapy for at least 6 months,
CD4þ cell counts higher than 500 cells/ml and CD4þ cell
nadirs higher than 350 cells/ml. Third, 20 healthy
individuals after receipt of informed consent according
to the ethic approval from the Ethikkommission
Nordwest und Zentralschweiz (EKBB 242/11). For both
latter groups, only one time point was analyzed. Baseline
characteristics of patients and healthy individuals are
included in the Supplementary table, http://links.lww.
com/QAD/A947.
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Generation of heat-inactivated C. albicans
A mixture of Candida albicans strain SC5314 yeast and
hyphae was cultured and heat-inactivated as previously
described [18,19].
Phenotypic characterization
T-cell activation/exhaustion was analyzed by staining
with anti-CD3-PerCP, anti-CD4-PacificBlue, anti-
CD8-APC, anti-CD25-PE/Cy7 and anti-CD279-PE
(PD-1); ILCs by staining with anti-Lineage-Cocktail-
APC (anti-CD3/CD14/CD16/CD19/CD20/CD56)
and anti-CD127-PE; NK-cell subsets by staining with
anti-CD3-PerCP, anti-CD14-FITC, anti-CD19-PE/
Cy7, anti-CD56-APC/Cy7, anti-CD16-PacificBlue
(all BioLegend, Fell, Germany), anti-NKG2A-APC
(clone 131411) and anti-NKG2C-PE (both R&D
Systems, Abingdon, UK) [20]. Samples were acquired
on a CyAn ADP Analyzer (Beckman Coulter, Nyon,
Switzerland) and data analyzed with FlowJo software
vX.0.7 (FlowJo, Ashland, Oregon, USA).
Enzyme-linked immunosorbent spot assay
IFN-g and IL-17 enzyme-linked immunosorbent spot
(ELISPOT; Mabtech, Nacka Strand, Sweden) were
performed according to manufacturer’s instructions as
previously published [21]. Briefly, 3–5 105 cells/well
were stimulated in duplicates withC. albicans [multiplicity
of infection (MOI) 0.05], 0.05mg/ml cytomegalovirus
(CMV) pp65 (JPT Peptide Technologies, Berlin,
Germany) or 0.5mg/ml staphylococcal enterotoxin B
(SEB; Sigma-Aldrich, Buchs, Switzerland) for 72 h. The
number of spot forming counts per well was counted
by ELISPOT reader (Cellular Technologies Ltd., Bonn,
Germany). Data are shown after subtraction of
unstimulated controls.
Proliferation assay
PBMC were labeled with carboxyfluorescein diacetate
succinimidyl ester (CFSE, Invitrogen, Fisher Scientific,
Reinach, Switzerland) according to manufacturer’s
instructions and stimulated with C. albicans (MOI 0.05)
or 0.5mg/ml SEB for 7 days in RPMI 1640 (Gibco,
Fisher Scientific, Reinach, Germany) with 5% pooled
human serum. Medium was replenished as needed. Cells
were stained with anti-CD3-PerCP, anti-CD4-Pacific-
Blue, anti-CD8-APC and anti-CD56-APC/Cy7 (all
Biolegend) and acquired on a CyAn ADP Analyzer
(Beckman Coulter) and data analyzed with FlowJo
software vX.0.7.
Statistical analysis
Comparisons between two groups were performed with
the two-sided Mann–Whitney U test. P values of 0.05 or
less were considered statistically significant. Statistical
analyses were done using GraphPad Prism 6.0f and Stata
13.1 software (StataCorp LP, College Station, Texas,
USA). Shown are median valuesþ interquartile ranges
(Tukey plots).
Results
Patients with Candida esophagitis have low and
dysfunctional CD4R cell counts and decreased
Candida-specific cytokine responses and
proliferative capacity
Wefirst analyzedT-cell phenotype and function of patients
diagnosed with Candida esophagitis and compared them
with HIV-1-infected individuals with early initiation of
cARTand sustained viral suppression (<50 copies/ml) and
healthy individuals (for baseline characteristics of patients
and healthy individuals see the Supplementary table,
http://links.lww.com/QAD/A947).
As expected from earlier studies, absolute CD4þ cell
counts were significantly lower in Candida esophagitis
patients compared with patients with early initiated
cART and healthy individuals (Fig. 1a) and the
frequencies of exhausted PD-1þ and activated/regulatory
CD25þ CD4þ cell counts were significantly increased
compared with healthy individuals (Fig. 1b). The median
percentage of CD25þ CD4þ cell counts was 6-fold
higher in patients with Candida esophagitis compared
with healthy individuals. In accordance with the
significantly reduced number of functional CD4þ cell
counts, the IFN-g and IL-17 responses of PBMC to the
superantigen SEB or C. albicans were significantly lower
in Candida esophagitis patients compared with patients
with early initiated cART and healthy individuals. The
IFN-g response to CMV pp65 in CMV seropositive
donors was not affected, showing that viral reactivation
was still able to trigger functional immune responses
independent of the CD4þ cell counts (Fig. 1c and d).
In line, the proliferative capacity of CD4þ and CD8þ cells
to C. albicans was significantly lower in patients with
Candida esophagitis compared with healthy individuals
(Fig. 1e and f). The median percentage of proliferating
CD4þ cell counts was 7-fold and of proliferating CD8þ
cell counts 12-fold decreased compared with healthy
individuals. Interestingly, CD4þ cell proliferation to SEB
was comparable to healthy individuals. To examine
whether the inability to proliferate was due to a lack of IL-
2 production, we supplemented some cultures with
50U/ml recombinant IL-2 on day 2. However, T-cell
proliferation was not improved (Supplemental Fig. 1,
http://links.lww.com/QAD/A920).
Thus, development of Candida esophagitis was associated
with reduced and dysfunctional CD4þ cell counts that
showed significant impairments in cytokine production
and proliferation to specific antigens.
Patients with Candida esophagitis have
decreased peripheral natural killer cells and
innate lymphoid cells
NK cells and ILC are increasingly considered as part of
the host defense against fungi. We therefore investigated
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whether these cells and their functionality are also
impaired in patients with Candida esophagitis.
Absolute NK-cell counts (CD3CD56þ) and especially
the cytotoxic CD16þ NK-cell subset were significantly
lower in patients withCandida esophagitis compared with
patients with early initiated cARTand healthy individuals
(Fig. 2a). The absolute number of CD16þ NK cells was
with a median of 42 cells/ml nearly 5-fold lower than in
healthy controls (201 cells/ml). The percentage of NK
cells expressing the inhibitory receptor NKG2A was
higher in cases with Candida esophagitis than in the other
groups, whereas the percentage of cells expressing the
activating receptor NKG2C was higher in Candida
esophagitis cases and in HIV-1-infected virologically
suppressed patients than in healthy individuals (Fig. 2b).
The proliferative capacity of NK cells to C. albicans was
not significantly affected (Fig. 2c).
Similar to NK cells, also peripheral ILC counts
(lineageCD127þ) were significantly reduced in patients
with Candida esophagitis compared with patients with
early initiated cART and healthy individuals (Fig. 2d).
In conclusion, additionally to defective CD4þ cell
responses, patients with Candida esophagitis had signifi-
cantly reduced numbers of NK cells and ILC.
The proliferative responses to C. albicans and
NK-cell counts and function are impaired despite
higher CD4R cell counts at diagnosis
Next, we examined whether higher CD4þ cell counts at
diagnosis ofCandida esophagitis are associated with better
functionality of the different cell subsets (Fig. 3).
Patients with CD4þ cell counts higher than 350 cells/ml
(18 of 37 patients) showed decreased percentages of
dysfunctional PD-1þ and CD25þ CD4þ cells and
increased cytokine responses to SEB and C. albicans
compared with patients with CD4þ cell counts less than
200 cells/ml (12 of 37 patients; Fig. 3a–c; the Supple-
mentary table, http://links.lww.com/QAD/A947). By
contrast, CMV-specific responseswere comparable regard-
less of the absolute CD4þ cell counts. The proliferative
response to C. albicans was reduced even in patients with
CD4þ cell counts higher than 350 cells/ml (Fig. 3d).
AlthoughNK-cell counts and the percentage of cytotoxic
CD16þ NK cells increased with higher CD4þ cell
counts, the absolute numbers of cytotoxic NK cells in
patients with CD4þ cell counts higher than 350 cells/ml
still remained more than 4-fold reduced compared with
healthy individuals (Fig. 3e). The number of ILC in
peripheral blood also significantly increased with higher
CD4þ cell counts (Fig. 3f).
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Fig. 1. Patients with Candida esophagitis have low and dysfunctional CD4R cell counts with decreased Candida-specific
cytokine responses and proliferative capacity. (a) Absolute CD4þ T-cell counts, (b) percentage of PD1þ and CD25þ CD4þ T cells,
(c) IFN-g response of peripheral blood mononuclear cell to staphylococcal enterotoxin B or heat-inactivated Candida albicans,
(d) IL-17 response of peripheral blood mononuclear cell to staphylococcal enterotoxin B or heat-inactivated C. albicans,
(e) percentage of proliferating (CFSEdim) cells in the CD4þ T-cell population after 7 days stimulation with staphylococcal
enterotoxin B or heat-inactivated C. albicans and (f) percentage of proliferating (CFSEdim) cells in the CD8þ T-cell population after
7 days stimulationwith staphylococcal enterotoxin B or heat-inactivatedC. albicans of patients at diagnosis ofCandida esophagitis
(ESO), patients with early initiated combination antiretroviral therapy and a viral load less than 50 copies/ml (viral load <50) and
healthy donors. Shown are median valuesþ interquartile ranges (Tukey plot). Data (c)–(f) are shown after subtraction of
unstimulated controls. Number of ESO/viral load less than 50/healthy donor were n¼37/15/20 (a), n¼33/15/20 (b), n¼ 18/
11/19 (c), n¼12/14/20 (d) and n¼4/8/14 (e and f). P0.05, P0.01 and P 0.0001 (Mann–Whitney test).
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These data highlight that CD4þ cell phenotype and
cytokine production and ILC counts normalized with
increasing CD4þ cell counts whereas the proliferative
capacity of CD4þ cells specifically to C. albicans and the
number of cytotoxic NK cells were strongly impaired in
all patients with Candida esophagitis irrespective of the
CD4þ cell count.
Patients with Candida esophagitis show a
significant drop in CD4R cell counts and nearly
abolished T-cell proliferation to C. albicans at
diagnosis and retain immunological impairments
even after disease resolution and successful
combination antiretroviral therapy
We further analyzed the immune status of patients with
Candida esophagitis prior to disease development to
identify immunological changes associated with disease
development and after disease resolution and successful
cART to identify possible long-term defects. We
therefore additionally examined PBMC 6–18 months
before diagnosis, after disease resolution (6–18 months
after diagnosis) and after successful cART with stably
suppressed HIV RNA (<50 copies/ml) for more than 2
years (Fig. 4).
Interestingly, the patients with Candida esophagitis
showed a significant drop in absolute CD4þ cell counts
at diagnosis and nearly abolished proliferation of CD4þ
and CD8þ cells in response to stimulation with C.
albicans. Proliferation to SEB was not significantly
affected. Also NK-cell proliferation in response to C.
albicans dropped during development of Candida eso-
phagitis (Fig. 4a,e,f,i).
In line with previous studies, Candida esophagitis
patients with low CD4þ cell nadirs (<320 cells/ml,
median 87 cells/ml) restored CD4þ cell counts after viral
suppression to a lower level compared with patients with
early cARTand higher CD4þ cell nadirs (>350 cells/ml,
median 397 cells/ml) (Fig. 4a). The percentage of CD25þ
CD4þ cell counts and the IFN-g responses to SEB andC.
albicans normalized after suppression of viral replication,
whereas the IL-17 response remained impaired despite
long-term viral suppression under cART (Fig. 4b–d).
The proliferative capacity of CD4þ cells to C. albicans
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after suppression of HIV replication recovered but
remained in median lower than in patients with early
initiated cART and healthy individuals (Fig. 4e and f).
Median NK-cell counts remained below 200 cells/ml
despite viral suppression. Although the percentage of
CD16þ cells increased, the absolute number of cytotoxic
CD16þ NK-cell counts remained more than 3.5-fold
lower compared with healthy individuals (Fig. 4g). By
contrast, the percentages of NKG2Aþ and NKG2CþNK
cells and the proliferative responses were comparable with
healthy controls (Fig. 4h and i). Similarly to NK cells, also
ILC counts remained 2.5-fold reduced for at least 2 years
after viral suppression (Fig. 4j). NK-cell and ILC
reconstitution seemed to correlate directly with CD4þ
cell reconstitution (Supplemental Fig. 2, http://
links.lww.com/QAD/A920).
The data show that development ofCandida esophagitis is
associated with a drop in absolute CD4þ cell counts and
proliferative capacity of Candida-specific T cells and that
despite successful cART, patients with previous Candida
esophagitis have prolonged immune defects of CD4þ
cells, NK cells and ILC.
Patients with similarly advanced HIV infection
but without an opportunistic infection show
overall better immune recovery after successful
combination antiretroviral therapy
The last comparator group consisted of patients with
similarly advanced HIV infection but without opportu-
nistic infection. These patients were matched to Candida
esophagitis patients according to CD4þ cell counts, use of
cART, sex, age and absence of other opportunistic
infection within 6 months prior to sample collection.
Also the viral load was comparable between these two
patient groups. Notably, patients with similarly advanced
HIV infection but without opportunistic infection
showed overall very similar immune cell impairments
and reconstitution as patients with Candida esophagitis
(Supplemental Fig. 3, http://links.lww.com/QAD/
A920). However, they differed by a 2-fold lower
percentage of CD25þ CD4þ cells prior to disease
development and consistently higher CD4RR cell
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proliferation to C. albicans. In addition, long-term
recovery of the IL-17 response, total NK cells, CD16þ
cytotoxic NK cells and ILCs was better in these patients
without Candida esophagitis.
Discussion
The detailed pathogenesis of opportunistic infections is
still unknown for many pathogens. Candida esophagitis is
one of the most frequent opportunistic diseases in
untreated HIV-infected individuals but also occurs in
patients with other underlying conditions.
In this study, we investigated in depth 37 HIV-1-infected
Candida esophagitis patients and compared them with
advanced HIV-1-infected patients without opportunistic
infection, HIV-1-infected patients with early initiation of
cART and healthy individuals. We found that patients
with Candida esophagitis showed a significant drop in
CD4þ cell counts at diagnosis, a nearly abolished
proliferative capacity to C. albicans, an impaired IFN-g
and IL-17 production to C. albicans and a dysfunction of
CD4þ cells with increased percentages of CD25þ and
PD-1þ cells. In addition, these patients had significantly
decreased peripheral ILC and cytotoxic NK-cell counts.
Recovery of the proliferative capacity of CD4þ ce and IL-
17 production to C. albicans and of ILCs and cytotoxic
NK cells was impaired for years despite effective cART.
HIV infection is commonly associated with an inability to
proliferate and produce IL-2. Even patients with normal
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IFN-g production often have a proliferative defect to
different antigens, especially patients with previously
low CD4þ cell counts and persistent HIV replication
[22–24]. In line with these data, we observed an overall
decreased proliferative capacity to Candida in patients
with Candida esophagitis at diagnosis and even after
recovery of the IFN-g response. These findings suggest
that the proliferative defect could contribute to disease
development and that these patients might remain
vulnerable despite effective cART.
CD4þ T cells from chronically infected HIV patients
show diminished IFN-g and IL-17 production [25], but
data on cytokine production in response to different fungi
in HIV-infected patients are scarce. This study demon-
strates that all patients with advanced HIV infection
including patients with and without Candida esophagitis
had an overall impaired IFN-g and IL-17 production to
C. albicans, which probably is partly due to the
significantly reduced CD4þ cell count. However, HIV-
infected patients with early initiation of cART had
comparable or even higher Candida-specific cytokine
responses compared with healthy individuals despite
significantly reduced CD4þ cell counts, showing that low
CD4þ cell counts do not necessarily lead to reduced
antigen-specific responses. Similarly, CMV pp65-specific
IFN-g production by CMV-seropositive patients was
comparable in all groups, independent of CD4þ cell
counts. It is however possible that patients with acute
Candida esophagitis have additional impairments in
antigen-presenting cells leading to reduced T-cell
responses or that Candida-specific T cells in these
patients are recruited to sites of infection and therefore
disappear from the blood. Interestingly, the recovery of
IL-17-producing cells was slower in patients withCandida
esophagitis compared with patients with advanced HIV
infection without opportunistic infection. These data
fortify previous findings in chronic mucocutaneous
candidiasis in humans and oropharyngeal candidiasis in
mice [9–11,25,26]. Interestingly, CMV pp65-specific
IFN-g production by CMV-seropositive patients was
comparable to healthy controls, showing that not all
antigen-specific responses are impaired in these patients.
[[NB change g in IFN-g to Greek gamma]].
We further found that patients with Candida esophagitis
had a significantly higher percentage of CD25þ CD4þ
cells before disease development compared with healthy
individuals. The patients with advanced HIV without
Candida esophagitis showed a 2-fold lower percentage
compared with the patients with Candida esophagitis. We
cannot state if these cells were activated or regulatory
T cells, as we did not include additional markers.
However, previous studies showed that a higher
percentage of regulatory T cells was associated with
lower HIV-specific and Candida-specific responses [27].
Furthermore, in-vitro depletion of the Treg-containing
CD25þ T-cell population greatly enhanced the response
to HIV and CMV antigens [28–30]. Moreover, PD-1þ
CD4þ cells significantly increased at diagnosis of Candida
esophagitis, which further supports the assumption that a
dysfunction of CD4þ cells might be one factor leading to
susceptibility to Candida esophagitis.
Healthy individuals also show proliferation of CD8þ cells
in response toC. albicans. Previous work in mouse models
has shown that in the absence of CD4þ cells, CD8þ cells
were able to confer protection to the fungal pathogens
Blastomyces dermatitidis and Histoplasma capsulatum [31].
Interestingly, in our study we did not observe compen-
satory proliferation of CD8þ cells in patients with low
CD4þ cell responses after stimulation withC. albicans. It is
possible that the CD8þ cells proliferating to C. albicans in
healthy individuals are mucosal-associated invariant
T cells that respond to C. albicans and are depleted in
the course of HIV infection [32–34].
Recently, it has been shown that not only Th17 cells, but
also other cells such as ILCs can be a source of IL-17 and
are involved in the host defense against fungal infections
[12]. We found that the ILC counts in peripheral blood of
Candida esophagitis patients were unable to recover even
with suppressed viral replication. Remarkably, patients
with CD4þ cell counts higher than 350 cells/ml had
significantly higher ILC counts in the peripheral blood
compared with patients with CD4þ cell counts less than
200 cells/ml, suggesting that the loss of ILCs occurs in
parallel with the loss of CD4þ cells over time and may
additionally increase the risk of developing Candida
esophagitis. Furthermore, recovery of ILCs after sup-
pressed viral replication seems to be correlated with
CD4þ cell recovery. Nevertheless, these data should be
interpreted with caution, as the number of patients is low,
and we did not investigate the different subsets of ILCs
and their involvement in the mucosa.
Also NK cells are increasingly considered as part of the
host defense against fungi [13,14,35–37]. Impaired NK-
cell activity was observed in patients with chronic
mucocutaneous candidiasis [38]. Also HIV-infected
individuals show quantitative and functional NK-cell
impairments that continue during disease progression,
such as a decrease of the CD3CD56þ cell subset, a
decreased cytotoxic capacity and aberrant expression of
several surface receptors [39–42]. In fact, we found
significantly lower NK-cell counts and a significantly
lower percentage of CD16þ cytotoxic NK cells in
patients with Candida esophagitis compared with healthy
individuals and patients with early initiated cART. They
also did not recover under stable, virologically successful
cART. Furthermore, similar to ILCs, NK-cell recovery
seemed to correlate with CD4þ cell recovery.
Recently, evidence has accumulated that early
initiation of cART is beneficial for virological as well
as immunological parameters. Early treatment decreases
1930 AIDS 2016, Vol 30 No 12
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cell-associated HIV RNA and DNA and limits the HIV
reservoir [43–47], maintains numbers and function of the
CD4þ cell compartment [4,48–50] and reduces the risk
for disease transmission and the development of
opportunistic viral and fungal infections and malignancies
[4,51,52]. However, it was not clear, how early or late
treatment affects T-cell responses to opportunistic
pathogens and how other immune cell subsets such as
NK cells or ILC are affected. In this study, we could
confirm improved overall and Candida-specific CD4þ
cell recovery in patients with early cART. We could
further show that ILC and NK-cell reconstitution,
immune cells with a likely role in antifungal defense,
correlated with CD4þ cell recovery and was therefore
superior in HIV-1-infected patients with early treatment,
further arguing for early initiation of cART in HIV-1-
infected individuals.
The strength of this study is the comprehensive
longitudinal analysis of quantitative and qualitative
immune responses in a large number of HIV-infected
patients withCandida esophagitis. This allowed identifying
significant immunological impairments compared with
healthy individuals and HIV-infected patients with early
initiation of cART.However, due to the limited availability
of PBMC, we did not further characterize different cell
subsets such as Treg or TH17 cells, and functional analysis
could not be performed in every sample.
In conclusion, this study demonstrates thatHIV-1-infected
patients with Candida esophagitis not only have deficient
T-cell responses, but an accumulation of multiple, partly
Candida-specific immunological defects. This may explain
the fact that despite the high frequency of Candida
esophagitis, only a part of AIDS patients develop this
opportunistic infection. These defects are only partially
reversible under cART, and long-term immune impair-
ments remain. This is particularly apparent in patients with
low CD4þ cell counts at initiation of cART showing
greater general andCandida-specific immune impairments
initially and under stable cART. Nevertheless, certain
individuals even experiencedCandida esophagitis at higher
CD4þ cell counts. These patients showed similar immune
defects as patients with low CD4þ cell counts highlighting
that the presence of specific immunological gaps is relevant.
We hypothesize that specific gaps due to underlying
genetic and/or immunological predisposition may explain
why certain individuals also develop opportunistic infec-
tion at higher CD4þ cell counts. In linewith other current
studies, our study similarly supports the rationale for early
initiation of cART.
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